bluebird bio Inc (OQ:BLUE)

Oct 09, 2019 08:00 am ET
bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including haemophilia. During the three-year research collaboration, bluebird and Novo Nordisk will focus on identifying a d
Sep 27, 2019 07:00 am ET
bluebird bio Appoints William R. Sellers, M.D. to Board of Directors
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed William R. Sellers, M.D. to its Board of Directors.
Sep 18, 2019 09:25 am ET
bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress
bluebird bio, Inc. (Nasdaq: BLUE) today announced updated results from the clinical development program for its investigational Lenti-D™ gene therapy in patients with cerebral adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress in Athens, Greece.
Sep 03, 2019 07:30 am ET
bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress
bluebird bio, Inc. (Nasdaq: BLUE) announced that updated data from the clinical development program for its investigational Lenti-D™ gene therapy in patients with cerebral adrenoleukodystrophy (CALD) will be presented at the 13th European Pediatric Neurology Society (EPNS) Congress, to be held September 17 – 21, 2019 in Athens, Greece.
Aug 22, 2019 04:05 pm ET
bluebird bio Announces Investor Events in September
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September:
Aug 01, 2019 04:36 pm ET
bluebird bio Reports Second Quarter 2019 Financial Results and Highlights Operational Progress
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2019.
Jun 14, 2019 05:31 am ET
bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA)
bluebird bio, Inc. (Nasdaq:BLUE) announced updated results from the completed Phase 1/2 Northstar (HGB-204) study, and new data from the Phase 3 Northstar-2 (HGB-207) and Phase 3 Northstar-3 (HGB-212) clinical studies of its LentiGlobin® gene therapy for patients with transfusion-dependent β-thalassemia (TDT),
Jun 14, 2019 05:31 am ET
bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress
bluebird bio, Inc. (Nasdaq:BLUE) announced new data from patients in Group C of its ongoing Phase 1/2 HGB-206 study of the company’s investigational LentiGlobin® gene therapy for sickle cell disease (SCD) today at the 24th European Hematology Association (EHA) Congress in Amsterdam, the Netherlands.
Jun 06, 2019 05:04 pm ET
bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) Approval
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting, and to discuss the approval of ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) on Friday, June 14 at 8:00 a.m. ET.
Jun 03, 2019 09:25 am ET
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependen
bluebird bio, Inc. (Nasdaq: BLUE) announced today that the European Commission (EC) has granted conditional marketing authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a gene therapy for patients 12 years and older with transfusion-dependent β-thalas
May 31, 2019 08:00 am ET
bluebird bio Announces Investor Events in June
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company will hold a conference call to discuss data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 14 at 8:00 am ET.
May 16, 2019 09:12 am ET
bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th
bluebird bio, Inc. (Nasdaq: BLUE) announced today that new data from its investigational gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) will be presented during the 24th European Hematology Association (EHA) Congress in Amsterdam, the Netherlands, June 13-16.
May 09, 2019 06:30 am ET
bluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies
bluebird bio, Inc. (Nasdaq: BLUE) today will host an Analyst Day in New York that will highlight significant progress in the company’s emerging immuno-oncology and severe genetic disease pipeline, provide updates on launch expectations for its first gene therapy product and share key aspects of its long-term growth strat
May 03, 2019 08:00 am ET
bluebird bio Announces Investor Events in May
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company will host an Analyst Day, Thursday, May 9, at 8:30 am ET at The Maxwell Hotel NYC, New York, NY.
May 02, 2019 04:05 pm ET
bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2019.
May 01, 2019 05:01 pm ET
Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal o
Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies’ lead investigational BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy candidate for patients with relapsed and refractory multiple myeloma.
May 01, 2019 08:00 am ET
bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer
bluebird bio, Inc. (Nasdaq: BLUE), has appointed Joanne Smith-Farrell, Ph.D., to chief business officer. In this role, Joanne will lead corporate development and strategy, and she will also continue to serve as our oncology franchise leader.
Apr 16, 2019 08:10 am ET
Consolidated Research: 2019 Summary Expectations for Nokia, bluebird bio, Verastem, Twilio, Logitech International S.A, and Rapid7 — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Nokia Corporation (NYSE:NOK), bluebird bio, Inc. (NASDAQ:BLUE),...
Mar 29, 2019 07:44 am ET
bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassem
bluebird bio, Inc. (Nasdaq:BLUE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization for ZYNTEGLO™ (autologous CD34+ cells encoding β A-T87Q-globin gene), a gene therapy
Mar 22, 2019 08:00 am ET
bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina
bluebird bio, Inc. (Nasdaq: BLUE) today announced the official opening of its first wholly owned manufacturing facility in Durham, N.C., that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin™ for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease.
Mar 08, 2019 08:00 am ET
bluebird bio to Present at Investor Conferences in March
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences:
Feb 21, 2019 04:05 pm ET
bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.
Feb 14, 2019 07:55 am ET
Report: Exploring Fundamental Drivers Behind Tyson Foods, ElectraMeccanica Vehicles, Cousins Properties, Spirit Aerosystems, bluebird bio, and Yext — New Horizons, Emerging Trends, and Upcoming Develo
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tyson Foods, Inc. (NYSE:TSN), ElectraMeccanica Vehicles Corp....
Feb 11, 2019 06:30 am ET
bluebird bio Appoints Chip Baird as Chief Financial Officer
bluebird bio, Inc. (Nasdaq:BLUE) announced Chip Baird will join the company effective today and assume the role of chief financial officer (CFO). Mr. Baird joins bluebird from Amicus Therapeutics, Inc., where he was the CFO for the past seven years and brings a demonstrated track record of successfully leading companies i
Jan 21, 2019 02:00 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the...
Jan 07, 2019 08:00 am ET
bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies
bluebird bio, Inc. (Nasdaq: BLUE) and Inhibrx, Inc. (Inhibrx) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Inhibrx’s proprietary single domain antibody (sdAb) platform to multiple cancer targets. The
Jan 03, 2019 10:30 am ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the...
Jan 03, 2019 08:00 am ET
bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 37th Annual J.P. Morgan Healthcare Conference, Tuesday, January 8, at 2:30 p.m. PT at the Westin St. Francis Hotel, San Francisco, followed by a question and answer breakout session at 3:00 p.m.
Dec 27, 2018 01:00 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the...
Dec 26, 2018 10:24 am ET
INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ:
Dec 24, 2018 03:35 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ:
Dec 24, 2018 01:40 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against bluebird bio, Inc. – BLUE
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of bluebird bio, Inc. (NASDAQ:BLUE) resulting from allegations that bluebird bio may have issued materially misleading business information to the investing public.
Dec 18, 2018 04:36 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE)
Law Offices of Howard G. Smith announces an investigation on behalf of Bluebird Bio, Inc. investors (“Bluebird” or the “Company”) (NASDAQ: BLUE) concerning the Company and its officers’ possible violations of federal securities laws.
Dec 17, 2018 12:46 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Bluebird Bio, Inc. investors (“Bluebird” or the “Company”) (NASDAQ:
Dec 14, 2018 11:43 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of bluebird bio, Inc.
Levi & Korsinsky announces it has commenced an investigation of bluebird bio, Inc. (“bluebird” or “the Company”) (NASDAQGS: BLUE) concerning possible violations of federal securities laws. On December 1, 2018, bluebird issued a press release...
Dec 13, 2018 02:14 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Bluebird Bio, Inc. investors (“Bluebird” or the “Company”) (NASDAQ:
Dec 12, 2018 06:42 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE)
Law Offices of Howard G. Smith announces an investigation on behalf of Bluebird Bio, Inc. investors (“Bluebird” or the “Company”) (NASDAQ: BLUE) concerning the Company and its officers’ possible violations of federal securities laws.
Dec 07, 2018 05:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of bluebird bio, Inc. – BLUE
Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
Dec 05, 2018 03:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE
NEW YORK, Dec. 5, 2018 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of  bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Dec 05, 2018 03:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE
NEW YORK, Dec. 5, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Dec 05, 2018 11:25 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of bluebird bio, Inc. (BLUE)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers bluebird bio, Inc. ("bluebird" or the “Company") (NASDAQ: BLUE). Such investors are encouraged to obtain additional information and...
Dec 03, 2018 09:15 pm ET
bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology
bluebird bio, Inc. (Nasdaq: BLUE) announced new data from patients in Group C of its ongoing Phase 1/2 HGB-206 study of the company’s investigational LentiGlobin™ gene therapy in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).
Dec 03, 2018 09:15 pm ET
bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent β-Thalassemia at 60th Annual Meeting of the American Society of Hematology
bluebird bio, Inc. (Nasdaq: BLUE) announced new data from the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) clinical studies of its investigational LentiGlobin™ gene therapy in the treatment of patients with transfusion-dependent β-thalassemia (TDT) at the 60th Annual Meeting of the America
Dec 02, 2018 07:30 pm ET
bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myel
bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed/refractory multiple myeloma. The data were presented by Nina Sh
Dec 01, 2018 05:00 pm ET
bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia and Sickle Cell Disease at 60th Annual Meeting of the American Society of He
bluebird bio, Inc. (Nasdaq: BLUE) announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell d
Nov 30, 2018 08:00 am ET
bluebird bio to Host Live Webcast of Investor and Analyst Event at the 60th Annual Meeting of the American Society of Hematology
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast of an investor and analyst event being held on Monday, December 3, 2018, during the 60th Annual Meeting of the American Society of Hematology (ASH). Speaker presentations will begin at 8:30 p.m. PST (11:30 p.m. EST) and
Nov 16, 2018 08:40 am ET
Market Trends Toward New Normal in PlayAGS, BEST, Inc. Sponsored ADR, Verrica Pharmaceuticals, Telenav, bluebird bio, and CompX International — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PlayAGS, Inc. (NYSE:AGS), BEST, Inc. Sponsored ADR (NYSE:BSTI), Verrica...
Nov 15, 2018 08:00 am ET
bluebird bio to Present at the Evercore ISI HealthCONx Conference
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the Evercore ISI HealthCONx Conference, Wednesday, November 28, at 4:15 p.m. ET at the Boston Harbor Hotel, Boston.
Nov 01, 2018 04:00 pm ET
bluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2018.
Nov 01, 2018 09:00 am ET
bluebird bio to Present New Data from Early- and Late-Stage Pipeline of Investigational Gene and Cell Therapies at the American Society of Hematology Annual Meeting
bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from its early- and late-stage investigational gene and cell therapy programs will be presented during the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 1 – 4.
Oct 05, 2018 05:00 am ET
bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia
bluebird bio, Inc. (Nasdaq: BLUE) announced today that the European Medicines Agency (EMA) accepted the company’s marketing authorization application (MAA) for its investigational LentiGlobin™ gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassemia (TDT) and a non-β0/β
Oct 01, 2018 08:00 am ET
bluebird bio to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, Wednesday, October 3, at 3:30 p.m. ET at the Lotte New York Palace, New York City.
Sep 05, 2018 06:11 am ET
bluebird bio Presents Updated Data from Phase 2/3 Starbeam Study of Investigational Lenti-D™ Gene Therapy for CALD and Initial Data from Observational Study ALD-103 of Allogeneic Hematopoietic Stem Ce
bluebird bio, Inc. (Nasdaq: BLUE) announced updated results from the Phase 2/3 Starbeam study (ALD-102) of its investigational Lenti-D™ gene therapy in boys 17 years of age and under with cerebral adrenoleukodystrophy (CALD), and initial data from ALD-103, the ongoing observational study of outcomes from allogeneic hematop
Aug 29, 2018 08:00 am ET
bluebird bio to Present at Investor Conferences in September
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences:
Aug 23, 2018 06:30 am ET
Aug 06, 2018 09:31 am ET
Thinking about buying stock in ACADIA Pharmaceuticals, bluebird bio Inc., Facebook, Netflix or NVIDIA?
CHICAGO, Aug. 6, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, BLUE, FB, NFLX, and NVDA....
Aug 06, 2018 06:30 am ET
bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
bluebird bio, Inc. (NASDAQ: BLUE) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human antibodies, as well as T cell receptors (TCRs) directed against tumor-specific proteins and peptides, and b
Aug 06, 2018 06:30 am ET
Aug 03, 2018 04:05 pm ET
bluebird bio to Present Updated Data for Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy at SSIEM 2018 Symposium
bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its clinical development program for its investigational Lenti-D™ gene therapy in pediatric patients with cerebral adrenoleukodystrophy (CALD) will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2018 Symposium held September 4
Aug 03, 2018 07:30 am ET
bluebird bio to Present at the 2018 Wedbush PacGrow Healthcare Conference
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference, Tuesday, August 14, at 8:35 a.m. ET at the Parker New York Hotel, New York City.
Aug 02, 2018 06:30 am ET
bluebird bio Reports Second Quarter 2018 Financial Results and Highlights Operational Progress
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2018.
Jul 27, 2018 04:05 pm ET
bluebird bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
bluebird bio, Inc. (Nasdaq: BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $162.50 per share.
Jul 26, 2018 04:30 pm ET
bluebird bio’s LentiGlobin™ Gene Therapy Granted Accelerated Assessment by European Medicines Agency for the Treatment of Transfusion-Dependent β-Thalassemia
bluebird bio, Inc. (Nasdaq: BLUE) today announced that its investigational LentiGlobin™ gene therapy for the treatment of adolescent and adult patients with transfusion-dependent β-thalassemia (TDT) and a non-β0/β0 genotype, was granted an accelerated assessment by the Committee for Medicinal Products
Jul 24, 2018 07:32 pm ET
bluebird bio Announces Pricing of Public Offering of Common Stock
bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 3,384,616 shares of its common stock at a public offering price of $162.50 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase up to an additional 507,692 shares of common stock. All of the shares in the offering are to be sold by bluebird bio.
Jul 23, 2018 04:01 pm ET
bluebird bio Announces Proposed Public Offering of Common Stock
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by bluebird bio.
Jun 28, 2018 07:40 am ET
Analysis: Positioning to Benefit within EMCOR Group, Ring Energy, A. O. Smith, bluebird bio, Ligand Pharmaceuticals, and Synovus Financial — Research Highlights Growth, Revenue, and Consolidated Resul
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EMCOR Group, Inc. (NYSE:EME), Ring Energy, Inc. (NYSE:REI), A. O. Smith...
Jun 15, 2018 06:00 am ET
bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association
bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the
Jun 15, 2018 06:00 am ET
bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the Eu
bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy
Jun 05, 2018 08:00 am ET
bluebird bio Announces Investor Events in June
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in June:
Jun 01, 2018 05:57 pm ET
Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple
Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced updated results from the ongoing CRB-401 phase I clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 43 patients with late-stage relapsed/refractory multiple
May 23, 2018 08:00 am ET
FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Lenti-D™ for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and life-threatening hereditary neurological disorder.
May 17, 2018 09:00 am ET
bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association
bluebird bio, Inc. (Nasdaq: BLUE) announced that data from ongoing LentiGlobin clinical studies in transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD) will be highlighted in oral presentations at the 23rd Congress of the European Hematology Association (EHA). An encore presentation of data f
May 16, 2018 05:00 pm ET
bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO
bluebird bio, Inc. (Nasdaq: BLUE) announced that updated interim data from CRB-401, its Phase 1 study of bb2121, an anti-BCMA CAR T cell therapy being developed by the company and Celgene, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
May 15, 2018 08:30 am ET
Investor Expectations to Drive Momentum within Aerohive Networks, M/I Homes, bluebird bio, Penske Automotive Group, Sanmina, and Genesco — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aerohive Networks, Inc. (NYSE:HIVE), M/I Homes, Inc. (NYSE:MHO), bluebird...
May 08, 2018 08:00 am ET
bluebird bio to Present at Investor Conferences in May
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences:
May 02, 2018 04:10 pm ET
bluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress
bluebird bio, Inc. (Nasdaq: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2018.
Apr 18, 2018 05:00 pm ET
bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemi
bluebird bio, Inc. (Nasdaq: BLUE) today announced interim data published in the New England Journal of Medicine (NEJM) from two separate two-year clinical studies investigating the potential for LentiGlobin™ gene therapy to eliminate or reduce chronic blood transfusions in patients with transfusion-dependent β-thalasse
Apr 16, 2018 08:00 am ET
bluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day
bluebird bio, Inc. (Nasdaq:BLUE) today announced that members of the management team will present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day on Tuesday, April 17, at 11:25 a.m. ET at the Metropolitan Club in New York City.
Mar 28, 2018 08:00 am ET
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with
Mar 07, 2018 08:00 am ET
bluebird bio to Present at Investor Conferences in March
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the following upcoming investor conferences:
Feb 21, 2018 04:05 pm ET
bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2017.
Feb 14, 2018 08:00 am ET
bluebird bio Appoints Alison Finger as Chief Commercial Officer
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today appointed Alison Finger as chief commercial officer. In this role, Alison will be responsible for shaping and deliverin
Feb 02, 2018 08:00 am ET
bluebird bio to Present at LEERINK Partners Global Healthcare Conference
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the LEERINK Partners 7th Annual Global Healthcare Conference, Wednesday, February 14, at 3:00 p.m. ET at the Lotte New York Palace, New York City.
Jan 31, 2018 07:40 am ET
Recent Analysis Shows Forward Industries, Sigma Designs, Northeast, bluebird bio, Walker & Dunlop, and Atmos Energy Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Forward Industries, Inc. (NASDAQ:FORD), Sigma Designs,...
Jan 17, 2018 08:31 am ET
Is it time to buy stock in bluebird bio Inc., Ford, The Goldman Sachs Group and Juno Therapeutics Inc?
CHICAGO, Jan. 17, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLUE, F, GS and JUNO....
Jan 08, 2018 04:05 pm ET
bluebird bio Announces Closing of Over-Allotment Option in Public Offering
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has issued an additional 277,109 shares of common stock at the public offering price of $185 per share, for total gross proceeds of approximately $51.3 million, pursuant to the partial exercise of the underwriters’ over-allotment option in connection with the company’s previously announced public offering of common stock. Afte
Dec 21, 2017 04:15 pm ET
bluebird bio to Present at Investor Conferences in January
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the following upcoming investor conferences:
Dec 12, 2017 08:46 pm ET
bluebird bio Announces Pricing of Public Offering of Common Stock
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of 3,243,244 shares of its common stock at a public offering price of $185 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase up to an additional 486,486 shares of common stock. All of the shares in the offering are to be sold
Dec 11, 2017 04:01 pm ET
bluebird bio Announces Proposed Public Offering of Common Stock
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an underwritten public offering of $600 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by bluebird bio.
Dec 11, 2017 09:00 am ET
bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent β-Thalassemia at American Society of Hematolog
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced updated data from the ongoing HGB-205 clinical study of its LentiGlobin gene therapy product candidate in patients wit
Dec 11, 2017 08:31 am ET
Thinking about investing in bluebird bio Inc., Celgene, Gilead Sciences, SunPower or Waste Management?
CHICAGO, Dec. 11, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLUE, CELG, GILD, SPWR, and WM....
Dec 10, 2017 04:30 pm ET
bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that updated clinical results from HGB-206, the company’s ongoing Phase 1 multicenter study of its LentiGlobi
Dec 10, 2017 04:30 pm ET
bluebird bio Presents New Data from Clinical Studies of LentiGlobin™ Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced data from two studies of its LentiGlobin gene therapy product candidate in patients with transfusion-dependen
Dec 10, 2017 10:30 am ET
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Mye
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented
Dec 07, 2017 08:00 am ET
bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
bluebird bio, Inc. (Nasdaq: BLUE) and Scottish immunotherapy company TC BioPharm, Ltd. (TCB) today announced a strategic collaboration and license agreement focused on gamma delta CAR T cells. The companies will work together to advance TC BioPharm’s lead CAR-engineered gamma delta T cell program into clinical trials as we
Nov 29, 2017 08:00 am ET
bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene and cell therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced it has acquired a 125,000-square foot manufacturing facility in Durham, North Carolina. Once constructi
Nov 22, 2017 08:30 am ET
New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of bluebird bio, Inc. (NASDAQ:BLUE), Accuray Incorporated...
Nov 22, 2017 07:40 am ET
New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of bluebird bio, Inc. (NASDAQ:BLUE), Accuray Incorporated...
Nov 16, 2017 08:30 am ET
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory
Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in previously treated patients with multiple myeloma, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) and PRIority MEdicines (PRIME) eligibility by the European Medicines Agency (EMA).
Nov 16, 2017 08:00 am ET
bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that the first patient has been treated in Northstar-3 (HGB-212), the company’s Phase 3 study of LentiGlobin
Nov 01, 2017 07:30 am ET
bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the third quarter ended September 30, 2017.
Nov 01, 2017 07:30 am ET
bluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed/Refractory Multiple My
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that four oral and seven poster presentations will feature data from bluebird programs during the 59th Annual Meeting of the American Society for Hematology (ASH). The data will highlight bluebird’s advancement of its LentiGlobin product candidate in patients with transfusion-dependent β-thalassemia (TDT) and severe sickle
Oct 31, 2017 04:05 pm ET
bluebird bio Announces ASH Abstract Conference Call on November 1st and Upcoming Investor Events in November
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the following investor events in November:
Oct 06, 2017 04:16 pm ET
bluebird bio to Present at Chardan Gene Therapy Conference
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Chardan Gene Therapy Conference on Tuesday, October 10, 3:00 pm ET at the Westin Grand Central, New York City.
Oct 04, 2017 03:00 pm ET
bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from an initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluati
Oct 04, 2017 03:00 pm ET
bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from an initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluati
Jun 08, 2017 10:31 am ET
Investors: Covered Call reports for Alcoa, bluebird bio Inc., Juno Therapeutics Inc, TG Therapeutics and XPO Logistics Inc include trade ideas that offer returns of 25% or more!
CHICAGO, June 8, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AA, BLUE, JUNO, TGTX, and XPO....
Dec 02, 2016 09:31 am ET
Fitbit, bluebird bio Inc., Johnson & Johnson, Skechers, and Diamond Offshore Drilling and more offer option-trading opportunities that offer returns of more than 20%
CHICAGO, Dec. 2, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLUE, DO, FIT, JNJ, and SKX....
Sep 16, 2016 10:31 am ET
InvestorsObserver releases covered-call reports for Alder Biopharmaceuticals, bluebird bio Inc., Expedia, Amgen and Computer Sciences Corporation
CHICAGO, Sept. 16, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALDR, AMGN, BLUE, CSC, and EXPE....
Sep 09, 2016 10:31 am ET
InvestorsObserver releases covered-call reports for Micron, bluebird bio Inc., Walgreens Boots Alliance, The Blackstone Group and Priceline
CHICAGO, Sept. 9, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLUE, BX, MU, PCLN, and WBA....
Sep 07, 2016 11:17 am ET
Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., as President and Chief Business Officer
CAMBRIDGE, Mass., Sept. 7, 2016 /PRNewswire/ -- Oncorus®, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme, today announced the appointment of Cyrus D. Mozayeni, M.D., as President and Chief Business Officer. Dr. Mozayeni will provide strategic leadership for the company, as well as have responsibility for corporate development, finance, legal, human resources and business operations. Dr. Mozayeni will rep...
Feb 02, 2016 09:31 am ET
Covered Call Alerts For Netflix, Google, Celldex Therapeutics, The Kroger Co and bluebird bio Inc. Released By InvestorsObserver
CHICAGO, Feb. 2, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NFLX, GOOGL, CLDX, KR and BLUE. ...